

Swiss university hospitals launch program to cut cancer cell therapy bill by two-thirds

Some of Switzerland's top university hospitals are teaming up to take on the soaring costs of cancer cell therapy offered by big pharma. They expect to reduce costs by treating cells in Switzerland instead of sending them abroad for genetic processing. Novartis sends blood to Germany for processing while Gilead Sciences Inc. sends cells to the U.S. for example.